CanBas Co., Ltd.
Tokyo Stock Exchange 4575.T
CanBas Co., Ltd. EPS (Diluted) for the year ending June 30, 2024: USD -0.42
CanBas Co., Ltd. EPS (Diluted) is USD -0.42 for the year ending June 30, 2024, a 26.54% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
-
CanBas Co., Ltd. EPS (Diluted) for the year ending June 30, 2023 was USD -0.58, a 11.56% change year over year.
-
CanBas Co., Ltd. EPS (Diluted) for the year ending June 30, 2022 was USD -0.65, a -3.21% change year over year.
-
CanBas Co., Ltd. EPS (Diluted) for the year ending June 30, 2021 was USD -0.63, a 18.64% change year over year.
-
CanBas Co., Ltd. EPS (Diluted) for the year ending June 30, 2020 was USD -0.77.
Key data
| Date | EPS (Diluted) | Shares (Diluted, Weighted) | Shares (Basic, Weighted) | Revenue |
|---|
Market news
Loading...
Tokyo Stock Exchange: 4575.T
| CEO | Mr. Takumi Kawabe M.D., Ph.D. |
| IPO Date | Sept. 17, 2009 |
| Location | Japan |
| Headquarters | 2-2-1, Otemachi |
| Employees | 11 |
| Sector | Health Care |
| Industries | |
Description
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email